ACSL Family Inhibitor

Triacsin C (WS 1228A), is an orally active and intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, which can be isolated from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity. Triacsin C exhibits highly inhibitory effect against rotavirus replication.

LIBX-A401 is a selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor with a human IC₅₀ values of 0.38 μM and a K_d of 0.72 μM. LIBX-A401 binds to ACSL4 in an ATP-dependent manner, stabilizes the C-terminal domain, alters the fatty acid gate region, and interacts with residues A329 and Q302 within the fatty acid binding site. LIBX-A401 exhibits anti-ferroptosis properties in cells. LIBX-A401 can be used for the researches of cancer and parkinson's disease.

ACSL5-IN-2 is a ACSL5 inhibitor that reduces the average body weight of diet-induced obese mice. ACSL5-IN-2 can be used for research on obesity.

Moracin N is a benzofuran compound. At low concentrations, Moracin N activates the Keap1/Nrf2 pathway, downregulates the expression of FTH1 and ACSL4, enhances glutathione synthesis, and inhibits neuronal ferroptosis. At high concentrations, Moracin N induces ROS accumulation, activates mitochondrial apoptosis, and triggers autophagy-mediated cell death by inhibiting the AKT/mTOR pathway. Moracin N can be used in research related to non-small cell lung cancer, hepatocellular carcinoma and ischemic brain injury.

LIBX-A403 is a potent, selective and reversible ACSL4 inhibitor with a human IC₅₀ of 0.049 μM and a K_d of 0.29 μM. LIBX-A403 binds in the ACSL4 fatty acid pocket in an ATP-dependent manner. LIBX-A403 prevents cell ferroptosis. LIBX-A403 can be used for the researches of cancer and parkinson's disease.

LP-856866 is an orally active ACSL5 inhibitor, with IC₅₀ values of 8 nM and 4 nM against mouse and human ACSL5, respectively, and IC₅₀ values of 6 nM and 17 nM against mouse and human ACSL1, respectively. LP-856866 induces delayed gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat mass, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic lipid accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable to research on diet-induced obesity.

LP-911888 is an orally active ACSL5/ACSL1 inhibitor, with IC₅₀ values of 1 nM and 3 nM against mouse and human ACSL5, and IC₅₀ values of 2 nM and 9 nM against mouse and human ACSL1, respectively. LP-911888 inhibits intestinal triglyceride uptake; it also reduces body weight and food consumption in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway. LP-911888 can be used in studies of diet-induced obesity.

DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease.

ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity. ACSL5-IN-1 inhibits ACSL5, an enzyme linked to fatty acid metabolism. ACSL5-IN-1 reduces body weight in diet-induced obesity mice. ACSL5-IN-1 can be used for the research of obesity, metabolic dysfunction-associated steatohepatitis, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes, acute myeloid leukemia, colorectal cancer, and breast cancer.

Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC).

ACSL4 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSL4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LIBX-A402 is a selective, ATP-dependent inhibitor of ACSL4 (hACSL4, IC₅₀=0.33 μM, K_d=3.3 μM) and an inhibitor of ferroptosis. LIBX-A402 targets the fatty acid-binding pocket of ACSL4 and prevents cells from undergoing ferroptosis. LIBX-A402 can be used in the research of cancer and Parkinson's disease.

Acsl4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Acsl4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Acsl4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Acsl4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

2-Phosphoglyceric acid (DL-2-phosphoglyceric acid) is a glycolytic substrate that is catalyzed by enolase to form phosphoenolpyruvate ester (PEP). 2-Phosphoglyceric acid inhibits the ferroptosis pathway by down-regulating ACSL4 and up-regulating GPX4, and has significant neuroprotective effects. 2-Phosphoglyceric acid reflects the overall metabolic state and flux of the cell.

ACSL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Acsl5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Acsl5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

ACSL3 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Acsl1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Acsl1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Acsl6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Acsl6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.